Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Immediate or delayed docetaxel: does progression-free survival really reflect two strategies?

Abali H, Disel U, Köse F, Sezer A, Mertsoylu H.

J Clin Oncol. 2009 Jun 10;27(17):2889; author reply 2889. doi: 10.1200/JCO.2009.22.3305. Epub 2009 Apr 27. No abstract available.

PMID:
19398567
2.

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES.

J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28.

PMID:
20038723
3.

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.

Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, Sakamoto T, Miura Y, Yomota M, Satoh A, Kunitoh H, Sakamaki K, Shibuya M, Watanabe K.

BMC Cancer. 2015 Oct 19;15:740. doi: 10.1186/s12885-015-1756-1.

4.

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH.

J Clin Oncol. 2009 Feb 1;27(4):591-8. doi: 10.1200/JCO.2008.17.1405. Epub 2008 Dec 15.

PMID:
19075278
5.

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.

Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group.

Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.

PMID:
26522337
6.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Singh N, Aggarwal AN.

Lancet. 2009 Feb 14;373(9663):541-2; author reply 542. doi: 10.1016/S0140-6736(09)60194-X. No abstract available.

PMID:
19217980
7.

Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.

Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T.

Oncologist. 2014 Apr;19(4):352-3. doi: 10.1634/theoncologist.2013-0411. Epub 2014 Mar 28.

8.

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M.

J Clin Oncol. 2008 Sep 10;26(26):4244-52. doi: 10.1200/JCO.2007.15.0185.

PMID:
18779611
9.

Maintenance chemotherapy in non-small cell lung cancer.

Eaton KD, Martins RG.

J Natl Compr Canc Netw. 2010 Jul;8(7):815-21. Review.

PMID:
20679540
10.

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G.

J Clin Oncol. 2012 Oct 10;30(29):3640-7. doi: 10.1200/JCO.2012.42.6932. Epub 2012 Sep 10.

PMID:
22965962
11.

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status.

Chen YM, Shih JF, Fan WC, Wu CH, Chou KT, Tsai CM, Lee YC, Perng RP, Whang-Peng J.

J Chin Med Assoc. 2011 May;74(5):209-14. doi: 10.1016/j.jcma.2011.03.005. Epub 2011 Apr 9.

12.

Reply to "Radiation pneumonitis and docetaxel".

Senan S.

Lung Cancer. 2004 Jan;43(1):117-8; author reply 119-20. No abstract available.

PMID:
14698546
13.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M.

J Clin Oncol. 2005 Nov 20;23(33):8389-95.

PMID:
16293869
14.

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.

Li X, Wang H, Lin W, Xu Q.

Curr Med Res Opin. 2014 Nov;30(11):2295-304. doi: 10.1185/03007995.2014.909392. Epub 2014 Apr 30. Review.

PMID:
24701984
15.

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.

Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D.

Cancer Treat Rev. 2006 Dec;32(8):583-7. Epub 2006 Aug 21.

PMID:
16919884
16.

A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.

Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S.

Chemotherapy. 2010;56(6):472-7. doi: 10.1159/000321016. Epub 2010 Nov 23.

PMID:
21099219
17.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY.

Lancet. 2008 Nov 22;372(9652):1809-18. doi: 10.1016/S0140-6736(08)61758-4.

PMID:
19027483
18.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Zalcman G, Bergot E.

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60192-6. No abstract available.

PMID:
19217981
19.

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.

Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM.

J Thorac Oncol. 2007 Jul;2(7):638-44.

20.

Nivolumab for squamous-cell non-small-cell lung cancer.

Yaqub F.

Lancet Oncol. 2015 Jul;16(7):e319. doi: 10.1016/S1470-2045(15)00033-9. Epub 2015 Jun 7. No abstract available.

PMID:
26062776

Supplemental Content

Support Center